3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
6
Sarcoma
4
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neurilemmoma
1
Nerve Sheath Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Meningioma
1
Male Urogenital Diseases
1
Lung Neoplasms
1
Locally Recurrent Rectal Cancer
1
Limited Stage Small Cell Lung Cancer
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Radiation Dose Hypofractionation
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled